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Background: Left ventricular noncompaction is very rare entity
with prevalence rate of 0.014–1.3% in western population. There is
no report from our country.
We report consecutive cases of isolated left ventricular noncom-
paction of SIX. We discuss historical, clinical, surface electrocar-
diogram, and echo-cardiographic features of this condition.
Result: One case has been linked with positive family history,
wherein father and son diagnose to have left ventricular noncom-
paction. In this series of cases, common localization of noncom-
pacted segments were in the apex and lateral wall of left
ventricular myocardium. Severe LV systolic dysfunction
(EF < 35%) seen in four cases. Grade II mitral regurgitation in four
cases and two cases had pulmonary artery hypertension.
Conclusion: High degree of suspicion in all cases of unexplained
severe left ventricular dysfunction is necessary to identify left
ventricular noncompaction.
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Background: Heart rate reduction has been proven to be of beneﬁt
in patients of chronic heart failure (HF). Despite advances in
management of HF, the morbidity and mortality remains high,
necessitating the development of novel therapeutic strategies.
Ivabradine is a selective sinus rate slowing agent which inhibits
the cardiac If current that is responsible for the spontaneous dia-
stolic depolarization in the sinus node. The role of ivabradine in HF
secondary to dilated cardiomyopathy (DCM) merits further study.
Methods: The study included 103 patients with DCM (mean age
47.9  14.8 years, NYHA class 3.2  0.4, BNP 742  489 pg/ml, LVEF
26.3  3.6%. Patients were randomized to receive ivabradine
(initiated at 2.5 mg BD titrated up to 7.5 mg BD at intervals of
2 weeks, titrated up to 7.5 mg BD, n = 52, Group 1) added to standard
therapy (beta blockers, ACE inhibitors, diuretics, n = 51, Group 2).
Functional class, BNP levels, and echocardiographic parameters
including LV volumes, LV end-systolic stress (LVESS), LVmass, LVwork,
and global LV strain were assessed at baseline, 3 months and 6
months follow-up.
Results: Baseline demographics including age, NYHA Class, BNP
levels, 6 min WT and MLWHF (Minnesota Living with HF ques-
tionnaire) scores were comparable between the two groups. There
was no difference in echocardiographic systolic and diastolic para-
meters amongst Groups 1 and 2 at baseline, including LVEF 26.06
 3.5% vs 26.7  3.1% ( p = 0.34), LVESS 205  44.3 vs 193  5.8
( p = 0.2), LV mass121.7  32 g vs126  39 g ( p = 0.5), LV work
531.2  146 vs 469  126 mmHg l/m ( p = 0.06), and LV global strain
10.4  1.3% vs10.1  1.6% ( p = 0.2). Themean dose of ivabradine
used was 12.1 mg  2.4 mg (range 5–15 mg); all patients tolerated
ivabradine well, except for rise in serum creatinine requiring with-
drawal of the drug in one patient.
3-months follow-up: Both groups had signiﬁcant improvement in mean
NYHA class (Gp 1 from 3.3  0.4 to 2  0, p = 0.001, Gp 2 from 3.2
 0.4 to 2  0.3, p = 0.03), 6 min walk test (Gp 1: 326  42 to 370
 38 m, p = 0.001, Gp 2: 336  76 to 364  77 m, p = 0.01), MLWHF
questionnaire (Gp 1: 74  14 to 58  11, p = 0.001, Gp 2: 78  8 to 65
 10, p = 0.001) and fall in BNP (Gp 1: 760  490 to 382  193 pg/ml,
p = 0.001, Gp 2: 724  492 to 420  289 pg/ml, p = 0.01). However, the
% change in 6 min WT, MLWHF and BNP was much higher in Ivabradine
group (+14%,21% and35%vs +9.4%,16% and30% respectively
with corresponding p values of 0.06, 0.02, 0.05). While both groups
demonstrated reduction in HR (95.6  12 to 80.3  7 bpm, p = 0.001 in
ivabradine group, 94.6  9 to 87.3  7 bpm, p = 0.001 in controls), the
% change was signiﬁcantly higher in the ivabradine group (15% vs
10.2%, p = 0.03). No signiﬁcant reduction in systolic or diastolic BP
was seen in the ivabradine group.
At 3 months, amongst those receiving ivabradine, there was sig-
niﬁcant improvement in indexed LV end-systolic (LVESVi, 86  19
to 73  15 ml/m2, p = 0.001) and LV end-diastolic volumes (LVEDVi
117  34 to 103  19 ml/m2, p = 0.001), MPI (0.82  1.2 to 0.7  0.1,
p = 0.001) and LVEF (26  3.5 to 29  3.6%, p = 0.001). The % change
in LVESVi, LVEDVi, MPI and LVEF was 15%, 15%, +11%, and
+12.2%, respectively. In contrast, amongst controls there was no
signiﬁcant change in LVESVi (83  20 to 81  21 ml/m2, p = 0.2),
LVEDVi (113  27 to 113  24 ml/m2, p = 0.9), MPI (0.79  1 to 0.75
 0.1, p = 0.06) and LVEF (26.7  3.7 to 26.7  4.5%, p = 0.9).
6months follow-up: At 6months, while both group of patients had
further improvement in NYHA class, 6 minWT, MLWHF score and
fall in BNP, the % change in all parameters was signiﬁcantly higher
with ivabradine group – (6 minWT: (19% vs 11.6%, p = 0.01, MLWHF
score 22% vs 16%, p = 0.01, fall in BNP 64% vs 31%, p = 0.001). At 6
months, the % reduction in HR was also signiﬁcantly greater in
those on ivabradine (19.5% vs 7.5%, p = 0.001). Importantly,
96.1% achieved HR < 70/min at 6 months on therapy with ivabra-
dine as compared to only 25.6% of those on standard treatment.
Age
(years)
Sex Clinical symptoms Localization of
non–compaction
LVF
EF-%
MR PA
Pressure
Inter
trabecular
recesses
Cardiomegaly
(chest X-ray)
ECG
Dyspnea Palpitation
25 M Class IV No Apex and lateral 30 Mild Normal 8 Yes Normal
56 M Class II No Apex and lateral 36 Mild Normal 6 Yes Normal
39 M Class II No Apex only 50 Trivial Normal 3 No Normal
39 M Class II No Apex only 48 Trivial 50 8 No Normal
65 F Class IV No Apex, lower end of
septum and lateral wall
32 Mild Normal 10 No Normal
74 F Class II No Apex and lateral 35 Mild 57 15 Yes Normal
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